

October 29, 2025

Q2FY26 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	ACCUMULATE		ACCUMULATE	
Target Price	782		821	
Sales (Rs. m)	10,448	12,140	10,733	12,574
% Chng.	(2.7)	(3.5)		
EBITDA (Rs. m)	2,068	2,443	2,130	2,534
% Chng.	(2.9)	(3.6)		
EPS (Rs.)	29.0	37.5	31.0	40.3
% Chng.	(6.4)	(6.8)		

Key Financials - Standalone

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	7,813	9,048	10,448	12,140
EBITDA (Rs. m)	1,416	1,750	2,068	2,443
Margin (%)	18.1	19.3	19.8	20.1
PAT (Rs. m)	606	732	964	1,247
EPS (Rs.)	18.2	22.0	29.0	37.5
Gr. (%)	(9.0)	20.7	31.7	29.4
DPS (Rs.)	2.0	4.0	6.0	7.0
Yield (%)	0.3	0.5	0.8	1.0
RoE (%)	9.8	10.9	13.0	15.0
RoCE (%)	12.1	13.8	16.0	18.3
EV/Sales (x)	3.3	2.9	2.5	2.1
EV/EBITDA (x)	18.4	14.8	12.4	10.3
PE (x)	40.2	33.3	25.3	19.5
P/BV (x)	3.8	3.5	3.1	2.8

Key Data

MOLT.BO | MTEP IN

52-W High / Low	Rs.893 / Rs.410
Sensex / Nifty	84,997 / 26,054
Market Cap	Rs.24bn/ \$ 276m
Shares Outstanding	33m
3M Avg. Daily Value	Rs.84.02m

Shareholding Pattern (%)

Promoter's	33.03
Foreign	20.08
Domestic Institution	10.96
Public & Others	35.93
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(1.1)	42.2	8.7
Relative	(6.5)	34.3	2.7

Vishwa Solanki

vishwasolanki@plindia.com | 91-22-66322244

Amnish Aggarwal

amnishaggarwal@plindia.com | 91-22-66322233

Parth Thakker

parththakker@plindia.com |

Near term outlook muted, Paints to drive growth

Quick Pointers:

- Pharma sales to clock Rs350mn+ in value for FY26
- EBITDA/KG to come in at Rs40-41 in 2HFY26 vs earlier guidance of Rs42-43

We cut our FY27/FY28 estimate by 6.4%/6.8% led by 1) Subdued near term outlook for paints with muted order flow from all players except ABG group 2) Persistent underperformance in lubes business & 3) lowered EBITDA/KG guidance of Rs40-41 for FY26 from earlier guidance of Rs42-43 led by higher competitive intensity in F&F & lower utilization. MTEP numbers were miss on our estimate as persistent rain drag the performance. EBITDA/kg came in at Rs39 vs Rs41/Rs35.8 in 1Q26/2Q25 as lower utilization led to subdued volume growth of 6.8%.

However, we believe LT drivers for MTEP remain intact given 1) rising business from leading paint and FMCG companies and scale up in pharma business. 2) Consistent addition of new customer with 5+ addition in Q2. & 3) Capacity enhancements at Cheyyar and Panipat with growing demand from ABG will enable increase in capacity utilization from Q4FY26 onwards. We estimate EBITDA/kg to increase to Rs43.7/46.2 over FY27 and FY28. We estimate a 15.8% Sales CAGR & 30.6% EPS CAGR over FY26-FY28. We assign a PE of 23.5x on Sep-27 valuing the company at Rs782 (Rs821 earlier). Retain 'Accumulate'.

Sales grew 9.6%, Volumes grew 6.8%: Revenues grew by 9.6% YoY to Rs2.1bn (PLe: Rs2.27bn). Gross margins expanded by 221bps YoY to 45.7% (PLe: 44.5%). EBITDA grew by 16.5% YoY to Rs391mn (PLe:Rs433mn); Margins expanded by 110bps YoY to 18.6% (PLe:19.0%). Adj PAT grew by 9.7% YoY to Rs155mn (PLe:Rs186mn)

Concall Takeaways: 1) The company reported a 6.8% YoY volume growth, as persistent rain and GST cut impacted the sales 2) Demand in October remains like September, while mgmt. remains confident for November & Q4. 3) Outlook in F&F remains positive in near term as new Panipat facility is set to contribute from Q3 onwards, further strengthening the capacity. 4) GST rate reductions on Food and FMCG ready-to-eat products is likely to increase demand for packaging solutions & company is well-positioned to capitalize on this trend, supported by its expanded capacity and diversified product portfolio. 5) The company continues to enhance its printing infrastructure by leveraging recent capacity additions. Company is continuously working on introducing next-generation IML printing technology, which will allow for lower Minimum Order Quantities (MOQs) and reduced production costs. 6) Sales from Grasim grew by 16% and with Capacity enhancements at Cheyyar and Panipat company might see better capacity utilization improvement. 7) During this quarter, the Company bagged new orders from reputed Companies like Veedol Corporation, Devee Agencies, Rallis India Limited, Ava Chalayil Health Care, Sri Balaji Process etc are from food industry and Pharmaforce. 8) CAPEX is likely to be at Rs1bn in FY26. 9) Mgmt guided for Rs40-Rs41 EBITDA/Kg for 2HFY26.

Exhibit 1: Sales up 9.6% YoY, EBITDA margins up by 110bps YoY

Y/e March	Q2FY26	Q2FY25	YoY gr. (%)	Q1FY26	H1FY26	H1FY25	YoY gr. (%)
Net Sales	2,098	1,913	9.6	2,406	4,503	3,880	16.1
Gross Profit	959	832	15.2	1,065	2,024	1,667	21.4
% of NS	45.7	43.5	2.21	44.3	44.9	43.0	2.0
Other Expenses	567	496	14.3	597	1,165	975	19.5
% of NS	27.1	25.9	1.11	24.8	25.9	25.1	0.7
EBITDA	391	336	16.5	468	859	693	24.0
Margins %	18.6	17.5	1.10	19.4	19.1	17.9	1.2
Depreciation	145	119	21.4	140	285	235	21.5
Interest	42	35	19.7	42	83	64	29.7
Other Income	4	6	(30.5)	6	10	15	(35.0)
PBT	208	187	11.4	300	508	409	24.3
Tax	53	46	16.5	76	129	102	26.5
Tax rate %	25.6	24.5	1.12	25.4	25.5	25.0	0.4
Adjusted PAT	155	141	9.7	216	379	306	23.6


Source: Company, PL

Exhibit 2: Overall volume went up by 6.8% in 2QFY26, Paints up 3.4%, F&F 14.4% and lubes decline 13.5%

Y/e March	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26
Volumes	8,602	9,071	9,894	9,381	9,247	9,734	11,378	10,018
YoY Change (%)	13.9	0.0	7.5	6.9	7.5	7.3	15.0	6.8
EBIDTA/ Kg	35.2	39.1	36.1	35.8	36.6	39.3	41.1	39.0
Growth %	-6.4%	-0.4%	-5.2%	-2.3%	3.8%	0.5%	13.9%	9.1%
Realization	-7.1	-4.3	-1.7	5.4	7.7	7.2	7.3	2.9
Paints	3800	4200	4483	4688	4439	4413	5593	4845
Growth %	0.1	-10.4	1.5	5.1	16.8	5.1	24.8	3.4
Volume Share	44.2%	46.3%	45.4%	49.4%	48.7%	46.0%	49.2%	49.6%
Lubes	2270	2350	2574	2052	2090	2455	2398	1776
Growth %	6.5	-1.9	-0.2	-5.1	-7.9	4.5	-6.8	-13.5
Volume Share	26.4%	25.9%	26.1%	21.6%	22.9%	25.6%	21.1%	18.2%
F&F	2532	2521	2818	2745	2589	2717	3196	3141
Growth %	56.0	26.9	26.7	27.3	2.3	7.8	13.4	14.4
Volume Share	29.4%	27.8%	28.5%	28.9%	28.4%	28.3%	28.1%	32.2%
Total Volume Tons	8602	9071	9875	9486	9118	9585	11187	9762
Vol Growth	13.9%	0.0%	7.1%	8.0%	6.0%	5.7%	13.3%	2.9%
Realization Growth	-7.1%	-4.3%	-1.3%	4.2%	9.3%	8.9%	9.0%	6.7%
Sales per kg (Rs)	192	195	199	202	209	211	215	215


Source: Company, PL

Exhibit 3: Foods business increased to 34.5% from 32.7%



Source: Company, PL

Exhibit 4: EBITDA/Kg came at Rs 39.0 in 2Q26



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	7,813	9,048	10,448	12,140
YoY gr. (%)	11.8	15.8	15.5	16.2
Cost of Goods Sold	4,403	5,029	5,793	6,719
Gross Profit	3,411	4,020	4,655	5,420
Margin (%)	43.7	44.4	44.6	44.6
Employee Cost	609	697	794	923
Other Expenses	-	-	1	1
EBITDA	1,416	1,750	2,068	2,443
YoY gr. (%)	6.4	23.5	18.2	18.1
Margin (%)	18.1	19.3	19.8	20.1
Depreciation and Amortization	487	588	639	692
EBIT	930	1,162	1,429	1,751
Margin (%)	11.9	12.8	13.7	14.4
Net Interest	139	198	161	121
Other Income	23	18	25	37
Profit Before Tax	813	982	1,293	1,667
Margin (%)	10.4	10.9	12.4	13.7
Total Tax	207	250	330	420
Effective tax rate (%)	25.5	25.5	25.5	25.2
Profit after tax	606	732	963	1,246
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	606	732	964	1,247
YoY gr. (%)	(9.0)	20.7	31.7	29.4
Margin (%)	7.8	8.1	9.2	10.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	606	732	964	1,247
YoY gr. (%)	(9.0)	20.7	31.7	29.4
Margin (%)	7.8	8.1	9.2	10.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	606	732	964	1,247
Equity Shares O/s (m)	33	33	33	33
EPS (Rs)	18.2	22.0	29.0	37.5

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	7,621	8,374	9,127	9,880
Tangibles	7,576	8,326	9,076	9,826
Intangibles	45	48	51	54
Acc: Dep / Amortization	2,192	2,779	3,420	4,113
Tangibles	2,168	2,751	3,386	4,074
Intangibles	23	28	33	39
Net fixed assets	5,430	5,595	5,707	5,767
Tangibles	5,408	5,575	5,690	5,752
Intangibles	21	20	18	15
Capital Work In Progress	304	150	200	200
Goodwill	-	-	-	-
Non-Current Investments	319	504	505	506
Net Deferred tax assets	(270)	(295)	(328)	(370)
Other Non-Current Assets	294	298	304	313
Current Assets				
Investments	-	-	1	1
Inventories	1,286	1,240	1,428	1,657
Trade receivables	1,353	1,735	2,004	2,328
Cash & Bank Balance	17	109	107	343
Other Current Assets	273	283	326	379
Total Assets	9,370	10,014	10,699	11,627
Equity				
Equity Share Capital	166	166	166	166
Other Equity	6,213	6,882	7,646	8,661
Total Networth	6,379	7,048	7,812	8,827
Non-Current Liabilities				
Long Term borrowings	694	700	500	200
Provisions	77	88	101	117
Other non current liabilities	57	53	53	53
Current Liabilities				
ST Debt / Current of LT Debt	1,063	950	900	900
Trade payables	444	441	508	589
Other current liabilities	384	438	495	569
Total Equity & Liabilities	9,369	10,013	10,697	11,626

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	813	982	1,294	1,668
Add. Depreciation	484	583	635	688
Add. Interest	139	198	161	121
Less Financial Other Income	23	18	25	37
Add. Other	27	1	6	6
Op. profit before WC changes	1,463	1,764	2,096	2,482
Net Changes-WC	(113)	(302)	(391)	(468)
Direct tax	(207)	(250)	(330)	(420)
Net cash from Op. activities	1,143	1,211	1,375	1,594
Capital expenditures	(1,420)	(585)	(790)	(741)
Interest / Dividend Income	23	18	24	36
Others	70	(185)	1	1
Net Cash from Invst. activities	(1,328)	(752)	(765)	(704)
Issue of share cap. / premium	(71)	4	(66)	(33)
Debt changes	494	(107)	(250)	(300)
Dividend paid	(100)	(66)	(133)	(199)
Interest paid	(139)	(198)	(161)	(121)
Others	-	-	1	1
Net cash from Fin. activities	184	(368)	(609)	(653)
Net change in cash	0	92	1	238
Free Cash Flow	(277)	626	585	853

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	18.2	22.0	29.0	37.5
CEPS	32.9	39.7	48.2	58.4
BVPS	192.0	212.1	235.1	265.6
FCF	(8.3)	18.8	17.6	25.7
DPS	2.0	4.0	6.0	7.0
Return Ratio(%)				
RoCE	12.1	13.8	16.0	18.3
ROIC	9.1	10.4	12.0	14.2
RoE	9.8	10.9	13.0	15.0
Balance Sheet				
Net Debt : Equity (x)	0.3	0.2	0.2	0.1
Net Working Capital (Days)	102	102	102	102
Valuation(x)				
PER	40.2	33.3	25.3	19.5
P/B	3.8	3.5	3.1	2.8
P/CEPS	22.3	18.5	15.2	12.6
EV/EBITDA	18.4	14.8	12.4	10.3
EV/Sales	3.3	2.9	2.5	2.1
Dividend Yield (%)	0.3	0.5	0.8	1.0

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q3FY25	Q4FY25	Q1FY26	Q2FY26
Net Revenue	1,907	2,026	2,406	2,098
YoY gr. (%)	15.2	14.6	22.3	9.6
Raw Material Expenses	1,046	1,144	1,341	1,139
Gross Profit	861	882	1,065	959
Margin (%)	45.1	43.6	44.3	45.7
EBITDA	338	383	468	391
YoY gr. (%)	11.6	7.9	31.0	16.5
Margin (%)	17.7	18.9	19.4	18.6
Depreciation / Depletion	124	128	140	145
EBIT	214	255	327	246
Margin (%)	11.2	12.6	13.6	11.7
Net Interest	34	40	42	42
Other Income	2	8	6	4
Profit before Tax	182	222	292	208
Margin (%)	9.5	11.0	12.1	9.9
Total Tax	45	60	76	53
Effective tax rate (%)	24.9	26.8	26.1	25.6
Profit after Tax	136	163	216	155
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	136	163	216	155
YoY gr. (%)	(3.9)	(9.5)	30.5	9.7
Margin (%)	7.2	8.0	9.0	7.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	136	163	216	155
YoY gr. (%)	(3.9)	(9.5)	30.5	9.7
Margin (%)	7.2	8.0	9.0	7.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	136	163	216	155
Avg. Shares O/s (m)	28	28	28	28
EPS (Rs)	4.9	5.9	7.8	5.6

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Oct-25	Accumulate	821	761
2	28-Jul-25	Accumulate	805	761
3	09-Jul-25	Accumulate	723	704
4	20-May-25	Accumulate	636	565
5	09-Apr-25	Accumulate	621	470
6	07-Feb-25	Accumulate	621	558
7	08-Jan-25	Accumulate	709	628
8	07-Nov-24	Accumulate	803	737

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Vishwa Solanki- PGDM - Finance, Mr. Amnish Aggarwal- MBA, CFA, Mr. Parth Thakker- BFM, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Vishwa Solanki- PGDM - Finance, Mr. Amnish Aggarwal- MBA, CFA, Mr. Parth Thakker- BFM, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com